Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Net Cash Flow: 2020-2024

Historic Net Cash Flow for Immuneering (IMRX) over the last 5 years, with Dec 2024 value amounting to -$23.3 million.

  • Immuneering's Net Cash Flow fell 4.94% to -$9.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$23.3 million, marking a year-over-year decrease of 75.81%. This contributed to the annual value of -$23.3 million for FY2024, which is 75.81% down from last year.
  • According to the latest figures from FY2024, Immuneering's Net Cash Flow is -$23.3 million, which was down 75.81% from -$13.2 million recorded in FY2023.
  • Immuneering's 5-year Net Cash Flow high stood at $37.8 million for FY2021, and its period low was -$23.3 million during FY2024.
  • Its 3-year average for Net Cash Flow is -$12.9 million, with a median of -$13.2 million in 2023.
  • Its Net Cash Flow has fluctuated over the past 5 years, first surged by 62.17% in 2021, then plummeted by 487.72% in 2023.
  • Over the past 5 years, Immuneering's Net Cash Flow (Yearly) stood at $23.3 million in 2020, then surged by 62.17% to $37.8 million in 2021, then plummeted by 105.96% to -$2.3 million in 2022, then slumped by 487.72% to -$13.2 million in 2023, then crashed by 75.81% to -$23.3 million in 2024.